Demand for glycerin as an ingredient in pharmaceuticals, personal care and other products is expected to show brisk growth out 2015, when demand around the world is expected to reach 3.39 billion pounds, according to market research firm Global Industry...
Merck Serono has begun work on the expansion of its Swiss biotech facility, with the additional capacity being used to meet rising demand for Erbitux (cetuximab).
GlaxoSmithKline (GSK) has proposed that it will close its facility in Dartford, UK in 2013, as the loss of patents for key drugs makes its operation uneconomical.
MonoSol Rx has entered into a partnership with Midatech to develop new drug formulations using the companies’ respective expertise in thin film delivery and biocompatible nanocells.
NeoStem has agreed to acquire China Biopharmaceuticals Holdings in an attempt to capitalise on the manufacturing and marketing opportunities in the nation.
AngioChem has posted findings that its lead candidate using its propriety technology for crossing the blood-brain barrier (BBB) is safe and well tolerated.
Isochem will have manufactured ten tonnes of the multi-purpose drug excipient vitamin E TPGS by the end of the year, marking the end of what it says has been a successful first 12 months of commercial scale production.
Bend Research is offering companies some of the drug delivery formulation expertise and technologies it developed during its 23 year collaboration with Pfizer.
The relentless commoditisation of glycerine ingredients prompted Dow Chemicals to all but exit the sector a few years back, but now the company says it is seeing a resurgence for its flagship synthetic glycerine brand.
Merck & Co has completed start-up activities at its vaccine manufacturing plant in Durham, North Carolina, which is intended to further the company’s ambitions in the sector.
US company Ferro has said it will sell off its fine chemicals division to private equity firm Arsenal Capital Partners, which will rename the business as Novolyte Technologies, for $66m.
The International Pharmaceutical Excipients Council (IPEC) of Europe has outlined the actions it is taking as it continues to develop awareness of the need for safe excipients.
Dow Chemical is hoping to push production of its Carbowax Sentry brand of polyethylene glycol ingredients up by a third over 2006/2007 levels by the end of the year, and put the production problems of recent months behind it.
Novozymes Biopolymer’s novel hyaluronic acid (HA) HyaCare has been named winner of this year’s gold innovation award at the CPhI worldwide conference in Frankfurt, Germany.
Alpharma has licensed an investigational transdermal bupivacaine patch from Durect for an initial $20m, with further payments based on reaching developmental milestones.
UK-based Reaxa and Switzerland’s RohnerChem have teamed up to develop the former’s EnCat catalyst technology for industrial applications in the API and drug manufacturing sector.
DSM Biomedical and Caliber Therapeutics aim to expand their presence in the balloon catheter market with a project to develop new drug delivery devices for vascular diseases, including atherosclerosis.
Exclusive interview with IPEC China chairman Nevin Cheng
IPEC China must become a “harmonisation bridge between China and other countries,” according to Colorcon’s Nevin Cheng who was recently elected chairman of the new organisation.
MannKind’s inhaled insulin treatment, Technosphere, has met its study goal in the first of three Phase III trials, leading to Pfizer transferring its remaining Exubera patients to the treatment.
Formatech hopes its new formulation method, which solubilises compounds in micelles consisting of fatty acids or alcohols, will improve both the safety and bioavailability of pharmaceutical products.
A surge in research into novel drug delivery systems will occur as companies seek to differentiate their products in response to pressure from biosimilars, according to a publication from Frost & Sullivan.
US drug delivery specialist MonoSol Rx says it has received USPTO patent rights to processes used in the manufacture of PharmFilm, its proprietary thin film drug delivery technology.
A nanoparticle capable of carrying a soluble and insoluble drug has been created for the delivery of combination therapies, according to research published in Nature.
CSL Biotherapies, part of Australia’s CSL group, has begun shipping the first of six million doses of its thimerosal-free vaccine Afluria to the US CDC ahead of this year’s flu season.
As the December 31 deadline for the removal of CFC albuterol inhalers in the US approaches, a new report by Kalorama Information forecasts big changes in the global $36bn (€26bn) a year respiratory products market.
The FDA has granted sNDA approval for Akorn’s IC-Green injection dye, which is the first lyophilised product manufacturered at the firm’s Decatur facility to gain such status.
Gene therapy could be advanced by a worm more commonly associated with causing a deadly parasitic disease, according to researchers presenting at the British Pharmaceutical Conference (BPC).
US fine and industrial chemicals specialist Aceto says that its expansion on the global stage, particularly in Europe and Asia, is starting to pay financial dividends.
Despite a decade-long build up, drugmakers are yet to wake up to the “no data, no market” mantra of the EC’s REACH legislation, according to SAFC’s marketing director Amanda Halford.
Drug delivery specialist BioAlliance Pharma says that its decision to focus on the oncology and infectious disease markets helped it reduce its half-year 2008 losses.
US fine chemical company Sigma-Aldrich said this morning that subsidiary SAFC Pharma has kicked off a $30m expansion plan for its active high-potency pharmaceutical ingredient (API) manufacturing facility in Madison, Wisconsin.
Codexis and Arch Pharmalabs’ expanded supply and development deal will see the latter produce APIs used in the manufacture of atorvastatin, principal component of Pfizer’s cholesterol buster Lipitor.
A facility operated by fatty acid specialist Equateq on the island of Lewis in Scotland has met with UK good manufacturing practice (GMP) standards for the production of lipid-based APIs for the drug industry.
